Fig. 1 · Structure

Documents & Downloads

Metformin HCl

Cat. No. A10573 CAS 1115-70-4
Metformin hydrochloride is a biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification.

In Stock

Publications for Metformin HCl

2 publications citing this product

  1. Matthew A Schaller, .et al. , JCI Insight, 2021, Sep 22;6(18):e148003 PMID: 34357881
  2. Matthew A. Schaller, .et al. , bioRxiv, 2021, January 21

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ma et al. reported direct binding of metformin to PEN2, with an estimated KD of 0.15 μM by surface plasmon resonance. A binding-site mutant showed little response in that assay. This affinity is an assay-specific binding measurement, not an AMPK activation potency. [1]

In primary mouse hepatocytes, 5 μM metformin for 2 h increased AMPKα and ACC phosphorylation in control cells; Pen2 loss blocked this low-dose response. Signaling at the higher 500 μM concentration was retained, showing that the PEN2 requirement depends on exposure. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AMPK (Hepatocytes)

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 208 μM Antiproliferative activity against human A549 cells by IncuCyte live-cell imaging assay [PMID: 33103432]
HEK293 IC50 1230 μM Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of MPP+ after 1 min [PMID: 28230985]
HEK293 IC50 250 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HepG2 EC50 0.27 μM Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 hrs [PMID: 21856048]
IGROV-1 IC50 850 μM Antiproliferative activity against human IGROV-1 cells incubated for 72 hrs by MTT assay [PMID: 33857729]
MCF7 IC50 9.9 nM Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay [PMID: 33479633]
PC-3 IC50 189 nM Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay [PMID: 33479633]
SK-OV-3 IC50 150 μM Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by MTT assay [PMID: 33857729]

In Vitro Studies

In non-diabetic mouse hepatocytes, metformin hydrochloride reduced basal and glucagon-stimulated glucose output and suppressed glucagon-induced G6pc and Pck1 expression. The matched glycinate comparator produced similar inhibition for these endpoints under the reported conditions. [2]

The salt comparison also revealed a model-dependent limit. Both formulations enhanced the insulin-associated AKT phosphorylation response in lean-control hepatocytes, whereas only glycinate significantly enhanced the 10 nM insulin response in db/db hepatocytes. Equivalent insulin sensitization by hydrochloride across these models is therefore not established. [2]

PEN2 binding measured by surface plasmon resonance

Biochemical assay · Purified FLAG-tagged PEN2 immobilized on a CM5 chip; PEN2-2A (F35A/E40A) and reference channel controls [1]

Metformin bound PEN2 in an SPR assay, whereas the PEN2-2A mutant showed little binding response. The reported affinity is assay-specific; it is not an AMPK activation EC50 or enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Metformin–PEN2 binding affinityKD 0.15 μM (estimated)[1]
Binding response of PEN2-2A relative to PEN2Qualitative specificity control PEN2-2A failed to bind metformin under the reported SPR conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.05, 0.78125, 1.5625, 3.125 and 6.25 μM
Exposure duration
150 s analyte flow per run
Method
BIAcore T200 SPR at 25 °C; reference-channel subtraction and global 1:1 Langmuir fit
Vehicle
PBS
Reported limits
No Adooq material or lot-specific characterization was reported for this experiment.
Methods and source locations

Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin

Evidence applies to the reported research material and model; it does not validate an Adooq lot.

Fig. 2f; Extended Data Fig. 6f; Results PEN2 binding paragraph; Methods SPR and Reagents

Metformin–PEN2 binding affinity: SPR; experiments performed in triplicate — Results PEN2 binding paragraph; Fig. 2f; Methods SPR

Binding response of PEN2-2A relative to PEN2: SPR comparison with F35A/E40A mutant; additional WT repeat sensorgrams — Extended Data Fig. 6f and caption

PEN2 dependence of low-dose AMPK signaling in mouse hepatocytes

Cell-based study · Primary mouse hepatocytes, wild-type/control versus Pen2-deficient [1]

At 5 μM for 2 h, metformin increased AMPKα and ACC phosphorylation in control hepatocytes, while the low-dose response was blocked by Pen2 loss. The 500 μM comparison retained signaling in deficient cells, limiting an absolute PEN2 requirement. Intracellular metformin uptake was not significantly altered by Pen2 loss in the associated control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AMPKα and ACC phosphorylation after metforminQualitative immunoblot response Low-dose response blocked by Pen2 knockout; high-concentration response retained[1]
Intracellular metformin in primary hepatocytes by genotypeGenotype comparison No significant uptake difference reported[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM; 500 μM high-concentration comparator shown in Fig. 2b
Exposure duration
2 h
Method
Immunoblotting for phosphorylated and total AMPKα/ACC with PEN2 control; associated intracellular metformin measurement
Reported limits
Fig. 2b does not explicitly specify the dosing vehicle; PBS used in the separate SPR assay is not assigned here. Four repetitions are stated for Fig. 2b, without a stated donor count in that caption.
Methods and source locations

Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin

Evidence applies to the reported research material and model; it does not validate an Adooq lot.

Fig. 2b and caption; Extended Data Fig. 3c,j; Methods Primary hepatocytes and Reagents

AMPKα and ACC phosphorylation after metformin: Total AMPKα and ACC and PEN2 assessed; Fig. 2b performed four times — Fig. 2b and caption

Intracellular metformin in primary hepatocytes by genotype: Intracellular metformin analysis; mean ± s.e.m., n = 4 per genotype; two-sided Student’s t-test — Extended Data Fig. 3j and caption

Hydrochloride and glycinate comparison in non-diabetic mouse hepatocytes

Cell-based study · Primary hepatocytes from non-fasted male C57BL/6 mice, age 8–12 weeks [2]

Both salts reduced glucose output in the mouse assay and suppressed glucagon-induced G6pc and Pck1 mRNA; the authors found no significant difference between salts for these endpoints. These endpoints do not demonstrate that AMPK activation is necessary for glucose suppression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal and glucagon-stimulated glucose outputDirection Reduced by metformin hydrochloride; similar inhibition reported for glycinate[2]
Glucagon-induced G6pc and Pck1 mRNADirection Decreased by both formulations without a significant between-formulation difference reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 or 1 mM for glucose output; 0.5 mM for mRNA
Exposure duration
3 h pretreatment; glucose output after a further 6 or 16 h; mRNA at 6 h
Method
Culture-medium glucose normalized to protein; RT-qPCR for G6pc/Pck1
Co-treatment
Separate salt-comparison arms, with or without 100 nM glucagon; salts were not combined.
Reported limits
Vehicle was not specified in the reviewed methods. Data are mean ± SEM from at least 3 independent experiments performed in duplicate; exact mouse/donor count per panel is not given.
Methods and source locations

Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin hydrochloride comparator

Evidence applies to the reported research material and model; it does not validate an Adooq lot.

Revision manuscript Fig. 1A–B and Results 3.1; Methods 2.1, 2.3, 2.6–2.9; PDF physical pp. 15–21

Basal and glucagon-stimulated glucose output: Glucose oxidase/peroxidase assay; glucose referred to total protein — Fig. 1A, Results 3.1 and Methods 2.6

Glucagon-induced G6pc and Pck1 mRNA: RT-qPCR; 0.5 mM formulation exposure and 100 nM glucagon — Fig. 1B and caption; Results 3.1; Methods 2.7, 2.9

Model-dependent insulin signaling after salt pretreatment

Cell-based study · Primary hepatocytes from male db/+ lean controls and db/db diabetic mice (C57BL/KsJ), age 8–12 weeks [2]

Both formulations enhanced the 10 nM insulin-associated AKT phosphorylation response in lean-control hepatocytes. In db/db hepatocytes, only glycinate significantly enhanced that response beyond insulin alone in the authors’ analysis; the hydrochloride effect should not be generalized as equivalent insulin sensitization in diabetic cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Additional enhancement of insulin-induced AKT Ser473 phosphorylation in db/db cellsComparative signaling response Significant enhancement at 10 nM insulin reported only with glycinate pretreatment[2]
Insulin-associated AKT Ser473 phosphorylation in db/+ cellsDirection Enhanced after pretreatment with either formulation at 10 nM insulin[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 mM of each salt in separate wells
Exposure duration
3 h low-glucose/serum-free conditioning, then 6 h salt pretreatment; insulin during the final 10 min
Method
Phospho-AKT Ser473 immunoblots with α-tubulin loading control
Co-treatment
Insulin 1 or 10 nM; matched no-insulin, insulin-only, and individual salt conditions
Reported limits
Vehicle not specified. Mean ± SEM of at least 3 independent experiments performed in duplicate; exact donor count per condition not specified. Immunoblot phosphorylation is not a direct AKT catalytic-activity assay.
Methods and source locations

Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin hydrochloride comparator

Evidence applies to the reported research material and model; it does not validate an Adooq lot.

Revision manuscript Fig. 6A–D and Results 3.6; Methods 2.1–2.3, 2.8–2.9; PDF physical pp. 30–32

Additional enhancement of insulin-induced AKT Ser473 phosphorylation in db/db cells: Immunoblot and densitometry; two-way ANOVA with Bonferroni post-hoc analysis — Fig. 6C–D; Results 3.6

Insulin-associated AKT Ser473 phosphorylation in db/+ cells: Immunoblot and densitometry with α-tubulin loading control — Fig. 6A–B; Results 3.6

In Vivo Studies

In male lean mice, a single oral dose of metformin hydrochloride tablets (100 or 200 mg/kg) improved oral glucose tolerance. Intestine-specific expression of metformin-insensitive NDI1 attenuated this effect, supporting a contribution from intestinal mitochondrial complex I. Resistance was incomplete, and the study does not establish equivalence to research-grade powder. [3]

Intestinal NDI1 attenuates acute metformin improvement of oral glucose tolerance

Animal study · Male lean standard-diet-fed Vil-Cre and intestine-specific Vil-Cre:NDI1 mice, age 7–10 weeks [3]

Intestine-specific expression of metformin-insensitive NDI1 attenuated metformin-induced improvement of oral glucose tolerance. The incomplete resistance supports a contribution from intestinal complex I without establishing it as the sole target. This is an acute tablet-formulation experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oral-glucose excursion and incremental AUC by genotypeQualitative genotype-dependent drug response Metformin effect attenuated in Vil-Cre:NDI1 mice relative to Vil-Cre controls; incomplete resistance[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
30 min before oral glucose (2 g/kg); blood glucose followed through 120 min after glucose
Vehicle
Water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
100 mg/kg: genotype comparison
100 mg/kg body weight
Water-treated animals of each genotype; Vil-Cre vehicle n = 14; Vil-Cre:NDI1 vehicle n = 10; Vil-Cre metformin n = 14; Vil-Cre:NDI1 metformin n = 9Metformin reduced glucose excursion/iAUC in controls, with an attenuated response in intestine-specific NDI1 mice. Resistance was incomplete.[3]
200 mg/kg: genotype comparison
200 mg/kg body weight
Water-treated animals of each genotype; Vil-Cre vehicle n = 11; Vil-Cre:NDI1 vehicle n = 11; Vil-Cre metformin n = 11; Vil-Cre:NDI1 metformin n = 13Metformin reduced glucose excursion/iAUC in controls, with an attenuated response in intestine-specific NDI1 mice. Resistance was incomplete.[3]
100 mg/kg: genotype comparison
Model: Male standard-diet-fed Vil-Cre controls and Vil-Cre:NDI1 mice, 7–10 weeks old
Reported limits: Commercial tablet preparation; excipient-matched placebo not described. No powder-to-tablet equivalence established.
200 mg/kg: genotype comparison
Model: Male standard-diet-fed Vil-Cre controls and Vil-Cre:NDI1 mice, 7–10 weeks old
Reported limits: Commercial tablet preparation; excipient-matched placebo not described. No powder-to-tablet equivalence established.
Methods and source locations

Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin

Evidence applies to the reported research material and model; it does not validate an Adooq lot.

Fig. 3a–d; glycaemic-control Results; Methods mouse model, drug preparation, glucose tolerance testing and statistics

Oral-glucose excursion and incremental AUC by genotype: Mean ± s.e.m.; two-way ANOVA with Bonferroni correction; exact values not inferred from curves — Fig. 3a–d and caption; Results glycaemic-control paragraphs

100 mg/kg: genotype comparison · Fig. 3a–b and caption; Methods drug preparation and glucose tolerance tests

200 mg/kg: genotype comparison · Fig. 3c–d and caption; Methods drug preparation and glucose tolerance tests

Specifications

Manufacturer Adooq Bioscience
CAS Number 1115-70-4
Formula C4H12ClN5
Molecular Weight 165.6
Synonyms Glucophage; Riomet; Diabex
SMILES
CN(C)C(=N)N=C(N)N.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Warmed: 30 mg/mL (181.14 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Ma, Teng, Tian, Xiao, Zhang, Baoding, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2 Nature (2022). PMID: 35197629 DOI: 10.1038/s41586-022-04431-8 Source material
  2. [2] Patricia Rada, Alejandra Mosquera, Jordi Muntané, et al. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice. Food and Chemical Toxicology (2019). PMID: 30414960 DOI: 10.1016/j.fct.2018.11.019 Source material
  3. [3] Sebo, Zachary L., Chakrabarty, Ram P., Grant, Rogan A., et al. Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control Nature Metabolism (2026). PMID: 42103929 DOI: 10.1038/s42255-026-01530-y Source material

Publications

2 publications citing this product

  1. Matthew A Schaller, .et al. , JCI Insight, 2021, Sep 22;6(18):e148003 PMID: 34357881
  2. Matthew A. Schaller, .et al. , bioRxiv, 2021, January 21

Added to your cart

View Cart Checkout
Loading...